SILO PHARMA INC (SILO) Fundamental Analysis & Valuation

NASDAQ:SILO • US82711P2011

Current stock price

0.3224 USD
-0.02 (-6.06%)
At close:
0.3373 USD
+0.01 (+4.62%)
After Hours:

This SILO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. SILO Profitability Analysis

1.1 Basic Checks

  • SILO had negative earnings in the past year.
  • SILO had a negative operating cash flow in the past year.
  • SILO had negative earnings in 4 of the past 5 years.
  • SILO had a negative operating cash flow in each of the past 5 years.
SILO Yearly Net Income VS EBIT VS OCF VS FCFSILO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M

1.2 Ratios

  • With a Return On Assets value of -79.51%, SILO is not doing good in the industry: 66.47% of the companies in the same industry are doing better.
  • SILO has a Return On Equity (-101.36%) which is in line with its industry peers.
Industry RankSector Rank
ROA -79.51%
ROE -101.36%
ROIC N/A
ROA(3y)-46.88%
ROA(5y)-66.86%
ROE(3y)-61.66%
ROE(5y)-80.07%
ROIC(3y)N/A
ROIC(5y)N/A
SILO Yearly ROA, ROE, ROICSILO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200 -250

1.3 Margins

  • SILO's Gross Margin of 65.42% is fine compared to the rest of the industry. SILO outperforms 79.77% of its industry peers.
  • SILO's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for SILO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.42%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.76%
GM growth 5Y29.76%
SILO Yearly Profit, Operating, Gross MarginsSILO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. SILO Health Analysis

2.1 Basic Checks

  • SILO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SILO has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for SILO has been increased compared to 5 years ago.
  • There is no outstanding debt for SILO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SILO Yearly Shares OutstandingSILO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
SILO Yearly Total Debt VS Total AssetsSILO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

  • Based on the Altman-Z score of -3.91, we must say that SILO is in the distress zone and has some risk of bankruptcy.
  • SILO's Altman-Z score of -3.91 is in line compared to the rest of the industry. SILO outperforms 42.77% of its industry peers.
  • SILO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.91
ROIC/WACCN/A
WACC8.92%
SILO Yearly LT Debt VS Equity VS FCFSILO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M

2.3 Liquidity

  • A Current Ratio of 8.70 indicates that SILO has no problem at all paying its short term obligations.
  • SILO's Current ratio of 8.70 is fine compared to the rest of the industry. SILO outperforms 75.53% of its industry peers.
  • SILO has a Quick Ratio of 8.70. This indicates that SILO is financially healthy and has no problem in meeting its short term obligations.
  • SILO's Quick ratio of 8.70 is fine compared to the rest of the industry. SILO outperforms 75.53% of its industry peers.
Industry RankSector Rank
Current Ratio 8.7
Quick Ratio 8.7
SILO Yearly Current Assets VS Current LiabilitesSILO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. SILO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 21.56% over the past year.
  • SILO shows a decrease in Revenue. In the last year, the revenue decreased by 0.00%.
  • SILO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.51% yearly.
EPS 1Y (TTM)21.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.88%
Revenue 1Y (TTM)0%
Revenue growth 3Y0.99%
Revenue growth 5Y12.51%
Sales Q2Q%0%

3.2 Future

  • Based on estimates for the next years, SILO will show a very negative growth in Earnings Per Share. The EPS will decrease by -21.62% on average per year.
  • Based on estimates for the next years, SILO will show a decrease in Revenue. The Revenue will decrease by 0.00% on average per year.
EPS Next Y-25%
EPS Next 2Y-13.39%
EPS Next 3Y-25.99%
EPS Next 5Y-21.62%
Revenue Next Year0%
Revenue Next 2Y0%
Revenue Next 3Y0%
Revenue Next 5Y0%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SILO Yearly Revenue VS EstimatesSILO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M
SILO Yearly EPS VS EstimatesSILO Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. SILO Valuation Analysis

4.1 Price/Earnings Ratio

  • SILO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SILO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SILO Price Earnings VS Forward Price EarningsSILO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SILO Per share dataSILO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

  • A cheap valuation may be justified as SILO's earnings are expected to decrease with -25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.39%
EPS Next 3Y-25.99%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SILO Dividend Analysis

5.1 Amount

  • No dividends for SILO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SILO Fundamentals: All Metrics, Ratios and Statistics

SILO PHARMA INC

NASDAQ:SILO (3/13/2026, 8:00:02 PM)

After market: 0.3373 +0.01 (+4.62%)

0.3224

-0.02 (-6.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-26
Inst Owners9.11%
Inst Owner Change-21.75%
Ins Owners1.67%
Ins Owner Change8.56%
Market Cap4.29M
Revenue(TTM)72.00K
Net Income(TTM)-5.08M
Analysts82.86
Price TargetN/A
Short Float %4.29%
Short Ratio0.44
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 59.64
P/FCF N/A
P/OCF N/A
P/B 0.86
P/tB 0.9
EV/EBITDA N/A
EPS(TTM)-0.93
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS0.01
BVpS0.38
TBVpS0.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.51%
ROE -101.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 65.42%
FCFM N/A
ROA(3y)-46.88%
ROA(5y)-66.86%
ROE(3y)-61.66%
ROE(5y)-80.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.76%
GM growth 5Y29.76%
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.7
Quick Ratio 8.7
Altman-Z -3.91
F-Score4
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.88%
EPS Next Y-25%
EPS Next 2Y-13.39%
EPS Next 3Y-25.99%
EPS Next 5Y-21.62%
Revenue 1Y (TTM)0%
Revenue growth 3Y0.99%
Revenue growth 5Y12.51%
Sales Q2Q%0%
Revenue Next Year0%
Revenue Next 2Y0%
Revenue Next 3Y0%
Revenue Next 5Y0%
EBIT growth 1Y-30.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-52.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.95%
OCF growth 3YN/A
OCF growth 5YN/A

SILO PHARMA INC / SILO Fundamental Analysis FAQ

What is the fundamental rating for SILO stock?

ChartMill assigns a fundamental rating of 3 / 10 to SILO.


What is the valuation status of SILO PHARMA INC (SILO) stock?

ChartMill assigns a valuation rating of 0 / 10 to SILO PHARMA INC (SILO). This can be considered as Overvalued.


Can you provide the profitability details for SILO PHARMA INC?

SILO PHARMA INC (SILO) has a profitability rating of 1 / 10.


What is the earnings growth outlook for SILO PHARMA INC?

The Earnings per Share (EPS) of SILO PHARMA INC (SILO) is expected to decline by -25% in the next year.